Eloxx Pharmaceuticals (DB:397) - Prezzo delle azioni, notizie e analisi

397 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Maggiori dettagli

397 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 93.07% all'anno

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( €6M )

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 2 più rischi

Eloxx Pharmaceuticals, Inc. Concorrenti

Biofrontera

XTRA:B8FK

€16.1m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.6m

Redx Pharma

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Eloxx Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$3.20
Massimo di 52 settimane	US$28.80
Minimo di 52 settimane	US$3.20
Beta	2.06
1Variazione di 1 mese	-17.66%
Variazione a 3 mesi	-76.37%
Variazione di 1 anno	-87.62%
3Variazione a 3 anni	-98.57%
Variazione a 5 anni	n/a
Variazione dall'IPO	-98.10%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	397	DE Pharmaceuticals	DE Mercato
7D	3,420.7%	1.2%	1.3%
1Y	-87.6%	-19.7%	7.9%

Ritorno vs Industria: 397 ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -19.7 % nell'ultimo anno.

Rendimento vs Mercato: 397 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.9 % nell'ultimo anno.

Volatilità dei prezzi

Is 397's price volatile compared to industry and market?
397 volatility
397 Average Weekly Movement	1,181.2%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 397 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di 397 è aumentata da 581% a 1181% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	28	Sumit Aggarwal	www.eloxxpharma.com

Eloxx Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Eloxx Pharmaceuticals con la sua capitalizzazione di mercato?
397 statistiche fondamentali
Capitalizzazione di mercato	€5.86m
Guadagni(TTM)	-€39.70m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.1x

Rapporto P/E

397 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
397 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$41.84m
Guadagni	-US$41.84m

Ultimi guadagni dichiarati

Sep 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-19.31
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-494.1%

Come si è comportato 397 nel lungo periodo?

Vedi performance storica e confronto

397 Panoramica delle azioni

Premi

Analisi del rischio

Eloxx Pharmaceuticals, Inc. Concorrenti

XTRA:B8FK

€16.1m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.6m

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

New 90-day high: €4.46

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €2.24

New 90-day low - €2.26

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Eloxx Pharmaceuticals, Inc. Riepilogo dei fondamenti

0.0x

-0.1x

Guadagni e ricavi